SMARCA2 and neoplasm: Immunohistochemically, the tumor cells totally lacked SMARCA4 and BRM (SMARCA2); were negative for TTF1, AE1/3, Claudin4, desmin, MyoD1, myogenin, CD99, CD56, and WT‐1 proteins; and were weakly positive for synaptophysin.